AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

12-week treatment course will go forward to phase III studies

Kris Kowdley of Virginia Mason Medical Center, Seattle. Photo by Liz Highleyman/
Keith Alcorn
Published: 26 April 2013

A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported at the 48th International Liver Congress 2013 (EASL) on Thursday in Amsterdam.

The results presented at the International Liver Congress provided extended follow up on results first presented at the American Liver Meeting in November 2012.

The preliminary presentation to that meeting showed that between 79 and 96% of previously untreated patients with genotype 1a HCV infection achieved a sustained virologic response (an undetectable viral load 12 weeks after completing treatment, or SVR12), depending on the duration of treatment and regimen to which they had been randomised. In previously untreated patients with genotype 1b infection 96 to 100% of patients achieved SVR12. In previously treated null responders 81 to 89% of genotype 1a patients and 100% of genotype 1b patients achieved SVR12.

At the International Liver Congress this week, Kris Kowdley of Virginia Mason Medical Center, Seattle, presented 24-week post-treatment follow-up data (SVR24) on 571 patients, showing very few cases of viral breakthrough or relapse between weeks 12 and 24 post-treatment. Three patients are reported to have experienced relapse during this period, while a further eight have still to return for follow up after week 12, and are counted as virologic failures in their absence.

The AVIATOR study was designed to compare six different interferon-free combinations of varying components or duration among previously untreated patients and three different regimens among prior null responders, with the aim of selecting future interferon-free combination regimens for testing in larger phase III studies.

The study compared combinations of:

  • The once-daily HCV protease inhibitor ABT-450 boosted by ritonavir.
  • The once daily HCV NS5A inhibitor ABT-267.

  • The twice-daily HCV non-nucleoside polymerase inhibitor ABT-333.

  • Ribavirin.

By intent-to-treat analysis in which all patients randomised to any of the study regimens were counted, regardless of whether they completed the treatment course or not, 96% of treatment-naïve patients and 93% of prior null responders achieved SVR24. One case of virologic relapse occurred in a patient who received this regimen, two weeks after completing treatment, and no cases of relapse occurred after week 12 in patients receiving this regimen.

As at week 12 post-treatment, there was no substantial difference between previously untreated patients and prior null responders in their response to therapy. SVR24 results by sub-genotype were available for 158 treatment-naive and 88 null responders among the 571 patients, and showed that, across all the study arms, 98% of genotype 1b patients and 91% of genotype 1a patients achieved SVR24. Among previous null responders, 97% of genotype 1b and 93% of genotype 1a patients achieved SVR24.

Sub-genotype was the baseline characteristic which had the most pronounced impact on the likelihood of achieving SVR24 in treatment-naive patients. There was almost no difference in SVR24 rates by gender or by stage of liver disease, but patients with baseline viral load below 7 log showed a trend towards higher rates of cure among both treatment-naive (94 vs 89%) and prior null responders (96 vs 91%).

However, any differences according to baseline characteristics need to be treated with caution because in the cases of baseline viral load and IL28B status the numbers of patients available for comparison are small. Similarly, the exclusion of cirrhotic patients from this study makes it premature to draw conclusions about the efficacy and safety of the study regimens in patients with the most advanced liver disease.

Data on 80 patients treated for 24 weeks with the regimen of ABT-450/r ABT-267, ABT-33 and ribavirin showed no substantive difference in SVR24 rates, when compared to 79 patients treated for 12 weeks with the same regimen. Ninety-three per cent of treatment-naive patients achieved SVR24 when treated for 24 weeks, compared to 99% of patients treated for 12 weeks. Among null responders, 98% of those treated with this regimen for 12 weeks achieved SVR24, compared to 93% of those treated for 12 weeks.

Dr Kowdley told the conference: “The incremental gain of treating from 12 to 24 weeks is small; 12 weeks of treatment seems quite satisfactory.”

Based on the results of the Aviator study, AbbVie has selected a 12-week regimen of all three investigational drugs plus ribavirin for further study in phase III licensing trials.

Treatment was well tolerated by most patients; only 2.4% of 247 patients with available safety data discontinued treatment due to adverse events, and four out of six discontinuations were judged to be due to the study drugs. The most common side-effects were headache (31.2%), fatigue (29.6%) and nausea (22.7%), but these were mild in most cases and did not lead to treatment discontinuation.

No grade 3 or 4 cases of anaemia were observed. Six of 247 patients developed bilirubin elevations between three and ten times above the upper limit of normal but these were not treatment-limiting, and all resolved spontaneously.


Kowdley K et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267 and ABT-33 +/- ribavirin in patients with chronic genotype 1 infection: results from the Aviator study. 48th International Liver Congress, Amsterdam, abstract 3, 2013.

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.